UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2022.

Commission File Number: 001-40627

SOPHiA GENETICS SA
(Exact name of registrant as specified in its charter)

Rue du Centre 172
CH-1025 Saint-Sulpice
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F  ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SOPHIA GENETICS SA

Date: January 10, 2022

By: /s/ Daan van Well
Name: Daan van Well
Title: Chief Legal Officer
<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Corporate presentation dated January 11, 2022</td>
</tr>
</tbody>
</table>
Democratizing Data-Driven Medicine Together

Dr. Jurgi Camblong, Co-Founder & CEO
J.P. Morgan Healthcare Conference - January 11, 2022
Cautionary Notices

This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this presentation. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this presentation to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

No offer to sell or buy
This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Other material information
This presentation does not contain all material information about SOPHIA GENETICS SA. No representations or warranties (expressed or implied) are made regarding the accuracy, completeness or reliability of the information contained in this presentation.

Research Use Only
SOPHIA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information included in this presentation is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
We believe there is an unprecedented opportunity to create a wiser and more sustainable healthcare system.
A Global, Leading Health Tech Company
Pioneering The Data-Driven Medicine Revolution

Nasdaq: SOPH

2011
Year Founded

500+
Employees Globally

70+
Countries

GENEVA
BOSTON
Headquarters

30%
of Employees Hold PhDs

790+
Hospitals, Labs & BioPharma Customers

As of December 31, 2021
SOPHiA’s Distinguished Team of Industry Leaders
The Diverse and Innovative Force Behind Our Company
Healthcare’s Challenging Ecosystem
Non-Standardized Methods of Data Generation Lead to Data Silos

Disconnected
Data silos
Single modality
Suboptimal ROI
Limited
Difficult to scale
Our Vision to Deliver a **Decentralized Solution**
Enhancing Patient Care, Diagnosis and Drug Development

Today  tomorrow

Disconnected

Data silos

Single modality

Suboptimal ROI

Limited

Difficult to scale

© SOPHIA GENETICS®
The SOPHiA DDM™ Platform

Our Cloud Native Consumption-Based Platform Developed to Unlock Data Silos and Allow Healthcare Professionals to Work Together Around the World

- Leverages AI to standardize complex multimodal data
- Improves and scales as more data is analyzed
- Amplifies network effects
- Designed to be safe and secure

SOPHiA GENETICS®
Adaptable and Scalable
For Data-Driven Clinical Insights

Enabled to compute more data volume, support additional data modalities and deploy new applications and functionalities
## Potential Applications Span the Oncology Continuum of Care

<table>
<thead>
<tr>
<th></th>
<th>Screening</th>
<th>Early Detection</th>
<th>Diagnosis</th>
<th>Therapy Selection</th>
<th>Monitoring</th>
<th>Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genomics Germline</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Genomics Somatic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiomics Somatic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Genomics impact in other categories offers significant opportunity

© SOPHIA GENETICS®
One Global, Collaborative Platform
Supporting Clinical and BioPharma Solutions

Translates data into actionable insights to support clinical experts in their fight against cancers and inherited diseases

Revolutionizes drug discovery, clinical development and commercialization of new drugs
Robust Body of Real-World Evidence
Momentum to Drive Accelerated Market Adoption

300+ Peer-Reviewed Publications

Genomics  Radiomics  Multimodal

Peer-Reviewed Publications

127 2021
91 2020
61 2019
28 2018

As of December 31, 2021
DEEP-Lung-IV Multimodal Clinical Study

Utilizing Machine Learning Models to Predict Response using Baseline Data has Potential to be Transformative

Study Outline

Multicenter observational study allowing analysis of the aggregation of multimodal data associated with the response to treatment and prognosis of patients with metastatic non-small cell lung cancer.

Aims to enroll 4,000 patients from approx. 30 sites worldwide.

Study Objectives

- Predict treatment response at first evaluation
- Predict Progression Free Survival (PFS) and Overall Survival (OS)
- Provide validated predictive models to deploy on CarePath

SOPHIA GENETICS®
Introducing CarePath: From Data to Insights to Data-Driven Medicine
Transforming Clinical Intelligence and SOPHiA’s Long-Term Opportunity Set

- More informed and evidence-based clinical decision making
- More responsive and patient-centric care
- Predictive and personalized medicine
Better Together
Leveraging Strategic Partnerships to Solve Unmet Healthcare Needs

SOPHiA GENETICS and GE Healthcare
A partnership intended to facilitate clinical trial precision and efficiency and make it easier and faster for clinicians to provide the integrated insights they need to stratify, treat and care for their patients more effectively.

Cloud-Based platform
Standardize, compute and analyze multimodal health data across hospitals and labs

Combined with

Cloud & On-Prem Analytics
Advanced visualization of radiomic data and the versatility of the Edison platform

The Key Enabler
Precision health partnership enabling deeper insights and better patient outcomes

SOPHiA GENETICS®
Continual Enhanced Efficiency
Driven by Powerful Network Effects

New Healthcare Institutions
Hospitals
Labs
Cancer Institutes
BioPharma

More Raw Digital Health Data Uploaded
More Analyses Performed

SOPHiA GENETICS™

More Patients Benefit From Better Care Through Data-Driven Medicine
More Anonymized Statistical Data Insights Accessed
This is Just The Beginning for SOPHiA
Market Leader with ~$35bn TAM and Growing

~$35 Billion
Total Addressable Market

~$21 Billion
Clinical Market

~$14 Billion
BioPharma Market

© SOPHiA GENETICS®
Platform Analysis Volume At All-Time Highs

Record Consumption Despite Market Challenges

-Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2016 2017 2018 2019 2020 2021

~32% Decline from COVID-19 Restrictions

~33% Recovery From Q2'20

~66k

© SOPHIA GENETICS
Our Land and Expand Revenue Build
A Hallmark Of Our Growth Algorithm

Steady growth is fueled by a balanced mix of drivers, de-risking reliance on a singular strategy

SOPHiA GENETICS®
Strategic Pillars For Long-Term Success
Committed to Attractive Sustainable Growth and Operational Excellence

- Extend Network Size
- Increase Usage of Network
- Expand Menu of Offerings
- Build Partnerships
- Develop BioPharma Market
- Excel Operationally

SOPHiA GENETICS®
Our Progress: **2021 Highlights**
A Milestone Year of Growth and Accomplishments

- **$263mm** gross proceeds raised through our IPO & concurrent private placement from GE Healthcare
- **~140%** net dollar retention (vs. 118% avg. of top 50+ cloud companies)
- **<1%** customer churn
- **30+** new products launched including HRD, TSO500
- **5 new partnerships** (GE, OncoDNA, IBEX, Agilent & ARCAGY)
Looking Ahead: Initiating 2022 Revenue Guidance

Continued Strong Momentum Expected

~66k
Q4 2021 Analysis Volume

240k+
2021 Analysis Volume

16
Q4 2021 New Logos Onboarded

$51.5mm – $54.0mm
Projected Total 2022 Revenue Range

SOPHiA GENETICS
THANK YOU